CUTANEOUS T CELL LYMPHOMA (CTCL)
Clinical trials for CUTANEOUS T CELL LYMPHOMA (CTCL) explained in plain language.
Never miss a new study
Get alerted when new CUTANEOUS T CELL LYMPHOMA (CTCL) trials appear
Sign up with your email to follow new studies for CUTANEOUS T CELL LYMPHOMA (CTCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare blood cancers: targeted drug shows promise
Disease control Recruiting nowThis study tests a drug called golidocitnib in people with slow-growing but hard-to-treat T/NK-cell lymphomas that have come back or not responded to prior therapy. About 48 adults will receive the drug to see if it can shrink tumors and control the disease. The goal is to improv…
Matched conditions: CUTANEOUS T CELL LYMPHOMA (CTCL)
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 04, 2026 16:19 UTC
-
Scientists seek samples to create targeted cancer killers
Knowledge-focused Recruiting nowThis study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers aim to use these samples to develop immunotoxins—a new type of drug that delivers a toxin directly to can…
Matched conditions: CUTANEOUS T CELL LYMPHOMA (CTCL)
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 13, 2026 15:59 UTC